Ablating CAR and integrin binding in adenovirus vectors reduces nontarget organ transduction and permits sustained bloodstream persistence following intraperitoneal administration

Molecular Therapy

Volumn 9, Issue 2, 2004, Pages 218-230

  Akiyama, Masaki ^a   Thorne, Stephen ^b,d   Kirn, David ^b,e   Roelvink, Peter W ^c   Einfeld, David A ^c   King, C Richter ^c   Wickham, Thomas J ^c  

^a Fuso Pharmaceutical Industries Ltd   (Japan)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c GENVEC INC   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adenovirus; Cancer; CAR; Gene therapy; Integrins; Intraperitoneal; Liver; Mesothelium; Ovarian; Targeting

Indexed keywords

ADENOVIRUS VECTOR; ALPHA5 INTEGRIN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; GENE PRODUCT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER LOCALIZATION; CANCER THERAPY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE TARGETING; GENE TRANSFER; GENETIC TRANSDUCTION; HISTOLOGY; IN VIVO STUDY; LIVER PARENCHYMA; MESOTHELIUM; MOUSE; NONHUMAN; PERITONEAL CAVITY; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; RECEPTOR BINDING; STATISTICAL SIGNIFICANCE; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE;

EID: 1342268968     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2003.10.010     Document Type: Article

References (71)

1. Wolf, J. K., and Jenkins, A. D. (2002). Gene therapy for ovarian cancer. Int. J. Oncol. 21: 461-468.
2. Bauerschmitz, G. J., et al. (2002). Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res. 62: 1266-1270.
3. Heise, C., Ganly, I., Kim, Y. T., Sampson-Johannes, A., Brown, R., and Kirn, D. (2000). Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status. Gene Ther. 7: 1925-1929.
4. Deshane, J., et al. (1995). Targeted tumor killing via an intracellular antibody against erbB-2. J. Clin. Invest. 96: 2980-2989.
5. Mahasreshti, P. J., et al. (2001). Adenovirus-mediated soluble flt-1 gene therapy for ovarian carcinoma. Clin. Cancer Res. 7: 2057-2066.
6. Kim, J., Hwang, E. S., Kim, J. S., You, E. H., Lee, S. H., and Lee, J. H. (1999). Intraperitoneal gene therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mouse. Cancer Gene Ther. 6: 172-1178.
7. Hwang, E. S., et al. (1998). The effects of the adenovirus-mediated wild-type p53 delivery in human epithelial ovarian cancer cell line in vitro and in vivo. Int. J. Gynecol. Cancer 8: 27-36.
8. Modesitt, S. C., Ramirez, P., Zu, Z., Bodurka-Bevers, D., Gershenson, D., and Wolf, J. K. (2001). in vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer. Clin. Cancer Res. 7: 1765-1772.
9. Song, K., Li, Z., Seth, P., Cowan, K. H., and Sinha, B. K. (1997). Sensitization of cisplatinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas. Oncol. Res. 9: 603-609.
10. Song, K., Cowan, K. H., and Sinha, B. K. (1999). In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts. Oncol. Res. 11: 153-159.
11. Kanamori, Y., et al. (1998). A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cis-diamminedichloroplatinum (ii) in p53-deleted ovarian cancer cells. Eur. J. Cancer 34: 1802-1806.
12. Rancourt, C., et al. (1998). Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin. Cancer Res. 4: 2455-2461.
13. Rosenfeld, M. E., et al. (1996). Adenoviral-mediated delivery of herpes simplex virus thymidine kinase results in tumor reduction and prolonged survival in a scid mouse model of human ovarian carcinoma. J. Mol. Med. 74: 455-462.
14. Tong, X., et al. (1999). Comparison of long-term survival of cytomegalovirus promoter versus Rous sarcoma virus promoter-driven thymidine kinase gene therapy in nude mice bearing human ovarian cancer. Hybridoma 18: 93-97.
15. Tong, X. W., et al. (1997). Human epithelial ovarian cancer xenotransplants into nude mice can be cured by adenovirus-mediated thymidine kinase gene therapy. Anticancer Res. 17: 811-813.
16. Zeimet, A. G., et al. (2002). Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas. Gene Ther. 9: 1093-1100.
17. Alvarez, R. D., et al. (2000). A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (ad21): a phase I trial. Clin. Cancer Res. 6: 3081-3087.
18. Alvarez, R. D., and Curiel, D. T. (1997). A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSVtk) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients. Hum. Gene Ther. 8: 597-613.
19. Alvarez, R. D., and Curiel, D. T. (1997). A phase I study of recombinant adenovirus vector-mediated delivery of an anti-erbB-2 single-chain (SFV) antibody gene for previously treated ovarian and extraovarian cancer patients. Hum. Gene Ther. 8: 229-242.
20. Barnes, M. N., Coolidge, C. J., Hemminki, A., Alvarez, R. D., and Curiel, D. T. (2002). Conditionally replicative adenoviruses for ovarian cancer therapy. Mol. Cancer Ther. 1: 435-439.
21. Buller, R. E., et al. (2002). A phase I/II trial of rad/p53 (Sch 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther. 9: 553-566.
22. Buller, R. E., et al. (2002). Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with Sch 58500. Cancer Gene Ther. 9: 567-572.
23. Deshane, J., et al. (1997). Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single-chain antibody for ovarian cancer gene therapy. Gynecol. Oncol. 64: 378-385.
24. Hasenburg, A., et al. (2002). Adenovirus-mediated thymidine kinase gene therapy for recurrent ovarian cancer: expression of coxsackie-adenovirus receptor and integrins alphavbeta3 and alphavbeta5. J. Soc. Gynecol. Invest. 9: 174-180.
25. Hasenburg, A., et al. (2001). Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year-follow-up. Gynecol. Oncol. 83: 549-554.
26. Hasenburg, A., et al. (2000). Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. Cancer Gene Ther. 7: 839-844.
27. Hasenburg, A., et al. (1999). Thymidine kinase (tk) gene therapy of solid tumors: valacyclovir facilitates outpatient treatment. Anticancer Res. 19: 2163-2165.
28. Wickham, T. J. (2003). Ligand-directed targeting of genes to the site of disease. Nat. Med. 9: 135-139.
29. Bergelson, J. M., et al. (1997). Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275: 1320-1323.
30. Tomko, R. P., Xu, R., and Philipson, L. (1997). HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl. Acad. Sci. USA 94: 3352-3356.
31. Wickham, T. J., Mathias, P., Cheresh, D. A., and Nemerow, G. R. (1993). Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73: 309-319.
32. Bai, M., Harfe, B., and Freimuth, P. (1993). Mutations that alter an Arg-Gly-Asp (RGD) sequence in the adenovirus type 2 penton base protein abolish its cell-rounding activity and delay virus reproduction in flat cells. J. Virol. 67: 5198-5205.
33. Dechecchi, M. C., Melotti, P., Bonizzato, A., Santacatterina, M., Chilosi, M., and Cabrini, G. (2001). Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J. Virol. 75: 8772-8780.
34. Dechecchi, M. C., Tamanini, A., Bonizzato, A., and Cabrini, G. (2000). Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology 268: 382-390.
35. Dmitriev, I., et al. (1998). An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. 72: 9706-9713.
36. Kelly, F. J., et al. (2000). Selectivity of tag-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro. Clin. Cancer Res. 6: 4323-4333.
37. Hemminki, A., et al. (2001). An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol. Ther. 4: 223-231.
38. Kim, J., et al. (2002). Targeting adenoviral vectors by using the extracellular domain of the coxsackie-adenovirus receptor: improved potency via trimerization. J. Virol. 76: 1892-1903.
39. Kim, J. S., Lee, S. H., Cho, Y. S., Choi, J. J., Kim, Y. H., and Lee, J. H. (2002). Enhancement of the adenoviral sensitivity of human ovarian cancer cells by transient expression of coxsackievirus and adenovirus receptor (CAR). Gynecol. Oncol. 85: 260-265.
40. Kanerva, A., et al. (2002). Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin. Cancer Res. 8: 275-280.
41. You, Z., Fischer, D. C., Tong, X., Hasenburg, A., Aguilar-Cordova, E., and Kieback, D. G. (2001). Coxsackievirus - adenovirus receptor expression in ovarian cancer cell lines is associated with increased adenovirus transduction efficiency and transgene expression. Cancer Gene Ther. 8: 168-175.
42. Kim, M., et al. (2002). The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur. J. Cancer 38: 1917-1926.
43. Kanerva, A., et al. (2002). Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol. Ther. 5: 695-704.
44. Vanderkwaak, T. J., et al. (1999). An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches. Gynecol. Oncol. 74: 227-234.
45. Blackwell, J. L., et al. (2000). Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluid. Hum. Gene Ther. 11: 1657-1669.
46. Bewley, M. C., Springer, K., Zhang, Y. B., Freimuth, P., and Flanagan, J. M. (1999). Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR. Science 286: 1579-1583.
47. Kirby, I., et al. (1999). Mutations in the DG loop of adenovirus type 5 fiber knob protein abolish high-affinity binding to its cellular receptor CAR. J. Virol. 73: 9508-9514.
48. Kirby, I., et al. (2000). Identification of contact residues and definition of the CAR-binding site of adenovirus type 5 fiber protein. J. Virol. 74: 2804-2813.
49. Roelvink, P. W., Mi Lee, G., Einfeld, D. A., Kovesdi, I., and Wickham, T. J. (1999). Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science 286: 1568-1571.
50. Santis, G., et al. (1999). Molecular determinants of adenovirus serotype 5 fibre binding to its cellular receptor CAR. J. Gen. Virol. 80 (Pt. 6): 1519-1527.
51. Einfeld, D. A., et al. (2001). Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J. Virol. 75: 11284-11291.
52. Alemany, R., and Curiel, D. T. (2001). CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther. 8: 1347-1353.
53. Leissner, P., et al. (2001). Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropism. Gene Ther. 8: 49-57.
54. Smith, T., et al. (2002). In vivo hepatic adenoviral gene delivery occurs independent of the coxsackievirus-adenovirus receptor. Mol. Ther. 5: 770-779.
55. Martin, K., Brie, A., Saulnier, P., Perricaudet, M., Yeh, P., and Vigne, E. (2003). Simultaneous CAR- and alpha v integrin-binding ablation fails to reduce Ad5 liver tropism. Mol. Ther. 8: 485-494.
56. Nakamura, T., Sato, K., and Hamada, H. (2003). Reduction of natural adenovirus tropism to the liver by both ablation of fiber-coxsackievirus and adenovirus receptor interaction and use of replaceable short fiber. J. Virol. 77: 2512-2521.
57. Schoggins, J. W., Gall, J. G., and Falck-Pedersen, E. (2003). Subgroup B and F fiber chimeras eliminate normal adenovirus type 5 vector transduction in vitro and in vivo. J. Virol. 77: 1039-1048.
58. Vigne, E., et al. (2003). Genetic manipulations of adenovirus type 5 fiber resulting in liver tropism attenuation. Gene Ther. 10: 153-162.
59. Setoguchi, Y., Jaffe, H. A., Chu, C. S., and Crystal, R. G. (1994). Intraperitoneal in vivo gene therapy to deliver alpha 1-antitrypsin to the systemic circulation. Am. J. Respir. Cell Mol. Biol. 10: 369-377.
60. Braet, F., and Wisse, E. (2002). Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp. Hepatol. 1: 1.
61. Cichon, G., et al. (2003). Titer determination of Ad5 in blood: a cautionary note. Gene Ther. 10: 1012-1017.
62. Shayakhmetov, D. M., and Lieber, A. (2000). Dependence of adenovirus infectivity on length of the fiber shaft domain. J. Virol. 74: 10274-10286.
63. Smith, T. A., et al. (2003). Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum. Gene Ther. 14: 777-787.
64. Lieber, A., et al. (1997). The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J. Virol. 71: 8798-8807.
65. Wolff, G., Worgall, S., van Rooijen, N., Song, W. R., Harvey, B. G., and Crystal, R. G. (1997). Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J. Virol. 71: 624-629.
66. Tao, N., et al. (2001). Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol. Ther. 3: 28-35.
67. Azzali, G. (1999). The lymphatic vessels and the so-called "lymphatic stomata" of the diaphragm: a morphologic ultrastructural and three-dimensional study. Microvasc. Res. 57: 30-43.
68. Ohtani, Y., Ohtani, O., Nakatani, T. (1995). Microanatomy of the rat diaphragm with special reference to the lymphatics and mesothelial stomata. Ital. J. Anat. Embryol. 100(Suppl. 1): 143-153.
69. Nagy, J. A., Herzberg, K. T., Masse, E. M., Zientara, G. P., and Dvorak, H. F. (1989). Exchange of macromolecules between plasma and peritoneal cavity in ascites tumor-bearing, normal, and serotonin-injected mice. Cancer Res. 49: 5448-5458.
70. Brough, D. E., Lizonova, A., Hsu, C., Kulesa, V. A., and Kovesdi, I. (1996). A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J. Virol. 70: 6497-6501.
71. Einfeld, D. A., Brough, D. E., Roelvink, P. W., Kovesdi, I., and Wickham, T. J. (1999). Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base. J. Virol. 73: 9130-9136.